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The 2 13' Century CuresAct encourages the Food and DrugAdministration to
consider "real-worldevidence" in its regulationof the safety and efficacy of drugs and
devices. Many have interpretedthis mandate to focus on non-randomizedobservational
research. However, we suggest that regulatoryscience must also move from rarefied
academic hospitals to community-based settings, where the vast majority ofpatients in
fact receive care in the fragmented U.S. healthcare system. This move is especially
important if innovations are to reach, and be validatedin, more diverse populations.A
solution can be found in the 183 Practiced-BasedResearch Networks ("PBRN"), i.e.,
groups of primary care clinicians and practices in all 50 states working to improve
clinical care and translateresearchfindings into practice. This symposium contribution
seeks to (1) describe some of the common shortcomingsof clinical trials, (2) explore the
opportunities and challenges posed by use of real-world evidence as a basisfor drug
and device regulation, (3) briefly describe the history and evolution of PBRA's, and (4)
articulate the challenges and opportunitiesfor using PBRA/s to fulfill the 2 1 t Century
CuresAct mandate for real-worldevidence.
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INTRODUCTION

The 2 1st Century Cures Act requires that the Secretary of the Department of
Health and Human Services consider whether to permit real-world evidence to support
new indications of a previously approved drug and/or to satisfy post-approval study
requirements.1 Real-world evidence is broadly defined as "data regarding the usage, or
the potential benefits
or risk, of a drug derived from sources other than traditional
2
clinical trials."
The academic medical center ("AMC") is the paradigmatic site to collect
clinical trial data. Yet out of 800 symptomatic people, only one will seek care in an
AMC. 3 Over 200 of those 800 people, however, will seek care at a physician's office,
100 of whom will seek care from a primary care physician.4 These physician clinics
reach more diverse ethnic, racial, and socioeconomic groups, and reach into more
isolated rural and tribal populations. 5 We suggest that this geographic gradient is an
overlooked dimension in the move towards real-world evidence.
PBRNs are groups of primary care clinicians and practices working together to
answer community-based healthcare questions and translate those research findings into
practice.6 The Agency for Healthcare Research and Quality ("AHRQ"), which
developed the PBRN initiative, supports the PBRN Resource Center, where 183 PBRNs
are registered, representing primary care medical practices from all 50 states, treating
over 24 million patients.7 PBRNs provide clinicians the opportunity to engage in
research that addresses quality improvement/assurance and evidence-based practice,
potentially improving the quality of care and reducing clinician burnout.8
Although PBRNs present a strong foundation for producing rigorous realworld evidence with proven success in generating knowledge, their potential has not yet
been fully realized. We suggest that Congress, the Food and Drug Administration
("FDA"), and public-private partnerships further invest in PBRNs as a way to implement
the call for real-world evidence in the approval and post-approval study requirements of
drugs and medical products.
This paper seeks to (1) describe some of the common shortcomings of
conventional clinical trial models, (2) explore the opportunities and challenges posed by
the inclusion of real-world evidence as a basis for drug regulatory decision-making, (3)
briefly describe the history and evolution of PBRNs and the type of research they have
conducted, and (4) the challenges and opportunities for using PBRNs to supply the realworld evidence needed under the

2 1st

Century Cures Act.

' 21 U.S.C. § 355g(a) (2018).
2Id.§ 355g(b).
' Larry A. Green et al., The Ecology ofMedical CareRevisited, 344 NEW ENG. J. MED. 2021, 2023
(2001).

4Id.

5See Elizabeth M. Seidler et al., GeographicDistribution of ClinicalTrialsMayLead to Inequities
in Access, 4 CLINICAL INVESTIGATION 373, 373 (2014); Debra Sprague et al., Barriersto Cancer Clinical
TrialParticipationAmong American Indian andAlaska Native Tribal College Students, 29 J. RURAL HEALTH

55, 56 (2013).
6

AGENCY FOR HEALTHCARE RESEARCH & QUALITY, AHRQ PUB. No. 01-P020, PRIMARY CARE

PRACTICE-BASED RESEARCH NETWORKS (2001).
7 Practice-Based Research Networks,

AGENCY

FOR

HEALTHCARE

RES.

&

QUALITY,

https://pbm.ahrq.gov [https:Hperma.cc/8YZT-P729].
' See generally Daniel M. Hartung et al., Role of Practice-Based Research Networks in
ComparativeEffectiveness Research,1 J. COMP. EFFECTIVENESS RES. 45 (2012).
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II.

SHORTCOMINGS OF CONVENTIONAL CLINICAL TRIALS

The FDA has acknowledged the substantial gap between evidence gathered
during clinical trials to support the approval of drugs and the evidence "needed to
support their optimal use in real-world environments." 9 The practical shortcomings of
clinical trials are well-established.10
The U.S. healthcare system is famously fragmented, in terms of financing,
access to care, professional practice, and integration of information technology
systems.11 One such fragmentation is that the research system is typically conducted
separately and apart from the delivery of healthcare.12
Thus, performing research tends to be like building a firehouse to fight a fireidentifying researchers, recruiting patients, administering the product, and measuring
outcomes, all aside from, and in parallel to, the treatment context. Accordingly, clinical
trials are limited, time consuming, and expensive. 13As National Institutes of Health
CNIH") Director Francis Collins has explained, "The average length of time from target
discovery to approval of a new drug currently averages -13 years, the failure rate
exceeds 95%, and the cost per successful drug exceeds $1 billion, after adjusting for all
of the failures." 14 These are symptoms of the more fundamental problem that drug
testing, even after the approval process, largely occurs in rarefied settings, with limited
numbers of patients primarily recruited from and to academic hospitals and their related
15
clinics.
Clinical trials, as they are traditionally and intentionally designed, often target
a defined, limited population of symptomatic patients and are implemented in artificial
environments that do not accurately or adequately model the reality of clinical practice
or patient experiences.16 These narrow parameters make it easier for sponsors to show
that the drug meets safety and efficacy requirements, but can be unrealistic if they
exclude those with common comorbidities, histories (e.g., heart attack or surgery), or
with lab values or clinical markers outside of a set range. 17 Moreover, the protocols for
the clinical trial may artificially inflate the treatment adherence from normal provider
care and patient use, given the necessary research staff and coordination to follow up
with study participants/patients. 18
In addition to these practical challenges, clinical trials are a source of the
geographic, racial, ethnic, and socioeconomic disparities in health outcomes observed
across populations. Researchers have identified patient, provider, institutional, and
'Rachel E. Sherman et al., AcceleratingDevelopment ofScientific Evidencefor MedicalProducts
Within the Existing U.S. Regulatory Framework, 16 NATURE REV. DRUG DISCOVERY 297, 297 (2017).
1oId.
11See generally EINER ELHAUGE, THE FRAGMENTATION OF U.S. HEALTH CARE: CAUSES AND
SOLUTIONS (2010); Kurt C. Stange, The Problem ofFragmentationand the Need for IntegrativeSolutions, 7
ANNALS FAM. MED. 100 (2009).
12 Stange, supra note 11.
13 Trudie Lang, Adaptive Trial Design: Could We Use This Approach to Improve Clinical Trials
in the Field of GlobalHealth?, 85 AM. J. TROPICAL MED. & HYGIENE 967, 967 (2011).
14 Francis S. Collins, Reengineering Translational Science: The Time Is Right, 3 SCI.
TRANSLATIONAL MED. (ISSUE 90), 90cm17,1 (2011).
15 See Eugene Fink et al., Selection of Patientsfor Clinical Trials: An Interactive Web-Based
System, 31 ARTIFICIAL INTELLIGENCE MED. 241, 241 (2004).
16 John P.A. Joannidis, Why Most Clinical Research Is Not Useful, 13 PLoS MED. (ISSUE
e1002049), 1 (2016).
17See Seidler et al., supra note 5.
18 Ze Zhang et al., Adherence Reporting in Randomized Controlled Trials, 11 CLINICAL TRIALS
195, 195 (2011) ("Of 111 RCT manuscripts included in the sample, 51 (45.9%) reported study-drug adherence
among participants. Studies that reported adherence results were more likely to report negative findings (i.e.,
no significant treatment effect in a superiority trial, non-equivalence in an equivalence trial) (p - 0.032).").
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community level barriers to clinical trial participation for historically underrepresented
groups and populations. 19 Geographically, clinical trials are substantially clustered in
urban areas with more healthcare facilities. 2 Yet, nearly one in five Americans live in
rural areas. 21 This limits the participation of rural patients, who tend
to be older, sicker,
22
and with lower educational attainment and socioeconomic status.
Studies have documented that across medical conditions examined and practice
settings, individuals of racial and ethnic minority groups are underrepresented in clinical
trials.23 Implicit and explicit biases on the part of physicians and other providers may
result in fewer minority patients referred to, or consented to, participate in clinical
trials. 24 Patients may also self-select along racial, ethnic, and socioeconomic lines, often
because of a lack of trust in the institutions of healthcare and biomedical science. 25 Trials
can impose costs on participating patients, despite study participant subsidies and
reimbursements, including missed work and lost income, child care, and transportation
to and from
study activities, all of which can deter the participation of lower-income
26
patients.
The foregoing limitations create two sorts of systemic problems: epistemic and
distributional. The epistemic problem is that, if rural, poor, indigenous, or non-white
populations are disproportionately excluded from clinical research, then we may not be
able to make valid and generalizable inferences about the safety and efficacy of the
tested products. 27 For all sorts of reasons-genetic, environmental, cultural, economic,
and behavioral-these populations have distinctive health problems, including different
prevalence, incidence rates, and health outcomes for conditions such as heart disease
and hypertension. 28 It turns out that drugs and devices may have different risk/benefit
19 See Angelica P. Herrera et al., DisparateInclusion of OlderAdults in Clinical Trials: Priorities

and Opportunitiesfor Policy and Practice Change, 100 AM. J. PUB. HEALTH (SUPPLEMENT 1) 5105, 5105
(2010).
21Seidler, supra note 5, at 376.
21

U.S. CENSUS BUREAU, CB16-210, NEW CENSUS DATA SHOW DIFFERENCES BETWEEN URBAN

AND RURAL POPULATIONS (2016).
22 NAT'L ADVISORY COMM. ON RURAL HEALTH & HUMAN SERVS., MORTALITY AND LIFE
EXPECTANCY IN RURAL AMERICA: CONNECTING THE HEALTH AND HUMAN SERVICE SAFETY NETS TO

IMPROVE

HEALTH

OUTCOMES

OVER

THE

LIFE

COURSE

(2015),

https://www.hrsa.gov/advisorycommittees/rral/publications/mortality.pdf.
21 See, e.g., Claudia Baquet et al., Recruitment and Participation in Clinical Trials: SocioDemographic,Rural/Urban,and Health CareAccess Predictors,30 CANCER DETECTION & PREVENTION 24
(2006); Allen L. Gifford et al., Participationin Research and Access to Experimental Treatments by HIVInfected Patients, 346 NEW ENG. J. MED. 1373 (2002); Caren Heller et al., Strategies AddressingBarriersto
Clinical Trial Enrollment of UnderrepresentedPopulations:A Systematic Review, 39 CONTEMP. CLINICAL
TRIALS 169 (2014); Vivek H. Murthy et al., Participationin Cancer Clinical Trials: Race-, Sex-, and AgeBased Disparities,291 JAMA 2720 (2004); Desiree Rivers et al., A Systematic Review of the Factors
Influencing African Americans'Participationin Cancer Clinical Trials, 35 CONTEMP. CLINICAL TRIALS 13
(2013).
24 See Lauren M. Hamel et al., Barriersto Clinical Trial Enrollment in Racial and EthnicMinority

Patientswith Cancer, 23 CANCER CONTROL 327 (2016) (finding that under enrollment in clinical trials is a
greater challenge among racial and ethnic minorities); Michelle van Ryn & Jane Burke, The Effect of Patient
Race and Socio-Economic Status on Physicians' Perceptionsof Patients, 50 SOC. SCI. & MED. 813 (2000)
(finding that although physicians expect themselves to be unaffected by a patient's social or demographic
characteristics, studies show that the expectations are unrealistic and that physicians are affected by a patient's
demographics when forming judgements about them).
25 Hamel, supra note 24, at 332.
26

Id.

21See Edward J. Mills et al., Barriersto Participationin Clinical Trialsof Cancer:A Meta-Analysis
and Systematic Review of Patient-ReportedFactors,7 LANCET ONCOLOGY 141, 141 (2006).
28 See Elizabeth Brondolo et al., Race, Racism, and Health: Disparities,Mechanisms, and

Interventions, 32 J. BEHAV. MED. 1 (2009) (finding that research demonstrates that racial and ethnic minorities
tend to experience negative health outcomes in the U.S.); Leonard E. Egede & Samuel Dagogo-Jack,
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tradeoffs for these populations. For example, in one systematic review of the literature,
Professor Lizzy Brewster and colleagues found that for black patients, commonly-used
drugs for hypertension were in fact no more effective than placebo, notwithstanding
their FDA-approval as generally effective.29
Accordingly, for its own funded research, the NIH has issued a policy to
"guarantee that women and minorities are included in human subject research and
requires inclusion 'in numbers adequate to allow for valid analyses of difference in
intervention effect.""'3 In contrast, the FDA only provides guidelines instructing
investigators to uniformly collect the racial and ethnic data of study participants, while
altogether failing to "address the level of participation of racial and ethnic groups in
clinical trials."3 1
Aside from the epistemic problems, the exclusion of certain populations
presents clear distributional problems. Participation in research is a primary way that
clinicians discover and implement innovations in healthcare.32 As Professor Everett
Rogers of the University of New Mexico explains in his seminal book on the diffusion
of innovation, between mere awareness that an innovation exists and the understanding
of how it works is the pivotal "procedural knowledge" about how to use the innovation.33
Participation in research provides exactly that experience, and unsurprisingly, "a partial
trial of the innovation leads to a choice to adopt or reject the innovation."34 Yet,
researchers from racial and ethnic minority groups tend to conduct and initiate fewer
clinical trials, and physicians from minority racial and ethnic groups tend to participate
less often than their white counterparts in clinical trials. "5This lack of concordance is
cited as a potential factor that influences the underrepresentation of racial and ethnic
minority patients in clinical trials and slower uptake once the innovation is proven safe
and effective. 36 The same may be true of rural and indigenous populations, who live far
from AMCs.
III.

THE MANDATE FOR REAL-WORLD EVIDENCE

Former FDA Commissioner Robert Califf explains the traditional approach:
"The evidentiary standard for initial marketing approval for drugs, biologics, or medical
devices is a high bar generally construed as two traditional randomized controlled trials
'37
[C'RCTs")] demonstrating benefit in terms of clinical outcomes important to patients.
Califf goes on to explain, "The classic construct invokes a hierarchy of evidence in

Epidemiology of Type 2 Diabetes: Focuson Ethnic Minorities,89 IVIED. CLINICS N. AM. 949 (2005) (finding
that the prevalence of type 2 diabetes is higher in racial and ethnic minorities than in whites).
29 Lizzy M. Brewster et al., Systematic Review: Antihypertensive Drug Therapy in Black Patients,
141 ANNALS INTERNAL MED. 614, 625 (2004).
" Sarah Malanga et al., Big DataNeglects PopulationsMost in Need ofMedical andPublic Health
Research and Interventions 16 (Ariz. Legal Studies Discussion Paper No. 16 -26, 2016).
'1U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: COLLECTION OF RACE AND ETHNICITY
DATA IN CLINICAL TRIALS (2005).

12 See Brian Oldenburg & Karen Glanz, Diffusion of Innovations, in HEALTH BEHAVIOR AND
HEALTH EDUCATION: THEORY, RESEARCH, AND PRACTICE 313 (Karen Glanz et al. eds., 4th ed. 2011).
EVERETT M. ROGERS, DIFFUSION OF INNOVATIONS 173 (5th ed. 2003).

Oldenburg & Glanz, supra note 32, at 318.
Kenneth Getz & Laura Faden, Racial DisparitiesAmong Clinical Research Investigators, 15
AM. J. THERAPEUTICS 3, 3 (2008).
6
Id. at4.
17 Robert M. Califf, Comparison of Observational Data and the ONTARGET Results for
Telmisartan Treatment of Hypertension: Bull's-Eye or Painting the Target Around the Arrow?, 178 JAMA
INTERNAL MED. 63, 63-64 (2018).
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which RCTs occupy the apex
of the evidence pyramid, with observational analyses
38
relegated to lower levels.
The 2 1st Century Cures Act, passed in late 2016, requires the FDA to develop
a regulatory framework for evaluating "real-world" data and evidence for new indicated
uses of approved drugs and to supplement or substantiate required post-approval
studies. 39 Real-world evidence, as defined in the Act, is broad and nearly unlimited: it
"means data regarding the usage, or the potential benefits or risks, of a drug derived
from sources other than traditional clinical trials." 4
The FDA's 2017 draft guidance, issued for medical devices, defines real-world
evidence as "the clinical evidence regarding the usage, and potential benefits or risks of
a medical product derived from analysis of real world data," which is in turn described
as "data relating to patient health status and/or the delivery of healthcare routinely
collected from a variety of sources."41 Accordingly, real-world data can be generated
from any type of study design-including randomized and observational studies-so
long as the data source is from routine patient care, and the 4 study
design utilized
2
realistically approximates the use of the drug in clinical practice.
One especially promising application of the real-world evidence idea is the use
of electronic health records showing the safety and efficacy of off-label use of a
previously-approved drug in the U.S. to then support an FDA application to bring those
off-label uses on-label.4 3 Dr. Michael Fralick and colleagues recently demonstrated just
such an approach, using an observational dataset to replicate the findings of randomized
trials that the FDA relied upon to approve a supplemental indication for the drug
telmisartan.44
The FDA has acknowledged a receptiveness to the use of real-world evidence.
As FDA's Principal Deputy Commissioner Rachel Sherman has argued, "The FDA
considers the totality of evidence when evaluating the safety and effectiveness of new
drugs ....

Data from a study are always assessed within the context of other available

data, never in isolation."45 For example, the FDA has relied on early phase marketing
studies that
address product use in broader, more realistic populations and clinical
46
settings.
Despite the excitement and opportunity posed by the use of real-world
evidence, certain limitations are widely acknowledged. Real-world sources of data, "are
not collected or organized with the goal of supporting research, nor have they typically
been optimized for such purposes . . . Most glaringly, without random assignment,
"7

8

d. at 63.

921 U.S.C. § 355g (2017).
40

Id. § 355g(b).

41 U.S. FOOD & DRUG ADMIN., USE OF REAL WORLD EVIDENCE TO SUPPORT REGULATORY
DECISION-MAKING

FOR

MEDICAL

DEVICES:

GUIDANCE

FOR

INDUSTRY

AND

FOOD

AND

DRUG

ADMINISTRATION STAFF (2017).

42Sherman, supra note 9, at 297-98.
41See, e.g., Christopher Robertson & Victor Laurion, Tip of the IcebergII How the Intended-Uses
PrincipleProducesMedicalKnowledge and Protects Liberty, 11 N.Y.U. J.L. &LIBERTY 770, 777-802 (2017)

(discussing the FDA's consideration of a supplemental indication for quetiapine).

44Michael Fralick et al., Use of Health Care Databasesto Support Supplemental Indications of
Approved Medications, 178 JAMA INTERNAL MED. 55 (2018).
41Sherman, supra note 9, at 297.
46
1Id. at 298.
4' Rachel E. Sherman et al., Real-World Evidence What Is it and What Can it Tell Us?, 375 NEW
ENG. J. MED. 2293, 2294 (2016).
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estimates of efficacy can be confounded by selection effects and other confounders, for
which statistical manipulation is an incomplete solution.48
Proffered suggestions for developing the infrastructure to support real-world
evidence include integrating data collection across electronic medical record ("EMVR")
platforms and large scale claims datasets, and the use of registries to "create a unified
system for monitoring the safety and effectiveness of medical devices."49 Administrative
claims data will have accurate diagnostic codes and disease endpoints as well as
information about whether a laboratory test was ordered, but not the results of such
testing. Conversely, data generated in medical records databases will have laboratory
results but lack specificity and reliable diagnoses.50
Beyond the use of large datasets, NIH efforts include developing large scale
distributed research networks to conduct "pragmatic clinical trials."51 Pragmatic clinical
trials seek to "inform decision-makers .... enroll a population relevant to the decision
in practice and representative of the patients or populations and clinical settings for
whom the decision is relevant; and ...streamline procedures and data collection ...or
measure a broad range of outcomes."52 Some have referred to the difference between
proving efficacy (a showing of some benefit in an ideal situation; the minimum FDA
requirement for marketing) and proving effectiveness ("measure[ing] the degree of
beneficial effect in real clinical practice").53
Pragmatic clinical trials are a way to achieve the goals of "real-world evidence"
without sacrificing the rigor of randomization. Rather than only randomizing individual
patients to a treatment or a control, clusters of patients can be randomized based on their
physicians or practice groups.54 These research methods are becoming particularly
common in the domain of primary care as they provide for greater flexibility in study
protocol.55
For example, Dr. Elsie Taveras of Massachusetts General Hospital, and her
colleagues, randomized 14 primary care practices in Massachusetts, covering 549
patients, to one of two obesity interventions, versus a third group assigned to customary
care. 56 The research team found that using both a computerized decision support system
for pediatric clinicians and providing support for families' self-guided behavior change
improved childhood body mass index.57 A similar study of transient ischemic attacks
(similar to strokes), randomized clinics to either using an electronic decision tool, or not,
and found that it improved guideline adherence, safely reduced treatment cost, and

4"See id.
49Id.
51See Carla Torre & Ana P. Martins, Overview of PharmacoepidemiologicalDatabases in the
Assessment of Medicines Under Real Life Conditions, in EPIDEMIOLOGY - CURRENT PERSPECTIVES ON
RESEARCH 5AND
PRACTICE 131, 138 (Nuno Lunet ed., 2012).
1
Robert M. Califf & Jeremy Sugarman, Exploring the Ethicaland Regulatory Issues in Pragmatic
Clinical Trials, 12 CLINICAL TRIALS 436, 437 (2015).
52 Id. at 438.
51 Marshall Godwin et al., Pragmatic Controlled Clinical Trials in Primary Care: The Struggle
Between External and Internal Validity, BMC MED. RES. METHODOLOGY, Dec. 22, 2003, at 1, 1.
54See Jeremy Sugarman & Robert M. Califf, Ethics andRegulatory Complexitiesfor Pragmatic
Clinical Trials, 311 JAMA 2381 (2014).
55 See Charles Weijer et al., The Ottawa Statement on the Ethical Design and Conduct of Cluster

Randomized Trials, 9 PLOS MED. (ISSUe e100 1346) 1 (2012); see also Sandra M. Eldridge et al., Lessonsfor
Cluster Randomized Trials in the Twenty-First Century: A Systematic Review of Trials in Primary Care, 1
CLINICAL TRIALS 80, 80 (2004).
56 Elsie M. Taveras et al., Comparative Effectiveness of Childhood Obesity Interventions in

PediatricPrimaryCare: A Cluster-Randomized Clinical Trial, 169 JAMA PEDIATRICS 535, 535 (2015).
57Id.
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lowered the risk of serious injury.58 These methods are even used to optimize how drugs
are used clinically, e.g., to reduce the inappropriate use of antibiotics.59 They have also
been used to test the safety and efficacy of vaccines. 6 Pragmatic trials are not, however,
commonly used for
the regulatory science of investigating the safety and efficacy of
61
drugs themselves.
IV.

PRACTICE-BASED RESEARCH NETWORKS

PBRNs are emerging as a primary solution to these problems, and should
become central players in the future of regulatory science. PBRNs are defined by AHRQ
as groups of ambulatory care practices that participate in defining and systematically
answering clinically relevant primary care questions to improve quality and patient
outcomes. 62 Given the movement toward real-world data, PBRNs seem to be an ideal
framework on which to develop and implement the real-world research capacity.
The practice of medicine has long depended on careful observation, but the
move from anecdote to data brought the profession into modernity. 63 As early as the turn
of the 2 0 th century, individual physicians systematically gathered, recorded, and
64
aggregated their patients' data as a means of investigating practice-driven questions.
Dr. Larry Green and Dr. John Hickner chronicle the impact of five family physicians,
65
whom they credit as the pioneers of practice-based research in the primary care setting.
"These doctors all wondered about their patients' problems, and they developed a
systematic means of gathering, recording, and aggregating data on their patients. ' 66 One
such practitioner, Dr. James Mackenzie, who practiced in England in the late 1 9 th and
early 2 0 th centuries, explained:
I had not been long in the practice when I discovered how defective
was my knowledge .... For some years I thought that this inability to

diagnose my patients' complaints was due to personal defects. But
gradually, through consultations and other ways, I 6came
to recognize
7
that the kind of information I wanted did not exist.

" See Annamarei Ranta et al., Cluster Randomized Controlled Trial of TIL Electronic Decision
Support in PrimaryCare, 84 NEUROLOGY 1545 (2015).
5' E.g., Daniella Meeker et al., Effect of Behavioral Interventions on InappropriateAntibiotic
PrescribingAmong PrimaryCarePractices:A Randomized Clinical Trial, 315 JAMA 562 (2016).
60 See, e.g., Anton Camacho et al., The Ring Vaccination Trial: A Novel Cluster Randomised
Controlled Trial Design to Evaluate Vaccine Efficacy and Effectiveness During Outbreaks, with Special
Reference to Ebola, 351 BMJ (ISSUE h3740) 1 (2015); Ana Maria Henao-Restrepo et al., Efficacy and
Effectiveness ofan rVSV-Vectored Vaccine ExpressingEbola Surface Glycoprotein: Interim Results from the
Guinea Ring Vaccination Cluster-RandomisedTrial, 386 LANCET 857 (2015).
61 See Ian Ford & John Norrie, Pragmatic Trials, 375 NEW ENG. J. MED. 454, 461-62 (2016);
Nikolaos A. Patsopoulos, A Pragmatic View on Pragmatic Trials, 13 DIALOGUES CLINICAL NEUROSCIENCE
217, 217-18 (2011).
62 AGENCY FOR HEALTHCARE RESEARCH & QUALITY, supra note 7.
6 Charles Rosenberg, A Therapeutic Revolution Revisited, in THERAPEUTIC REVOLUTIONS:
PHARMACEUTICALS AND SOCIAL CHANGE IN THE TWENTIETH CENTURY 302, 304 (Jeremy A. Greene et al.
eds., 2016).
64 See id.; see also Larry A. Green & John Hickner, A Short History of Primary
Care PracticeBased Research Networks: From Concept to EssentialResearch Laboratories, 19 J. AM. BOARD FAM. MED.
1,1-2 (2006).
65 Green & Hickner, supra note 64, at 1.
66 Id.
67 Id. (quoting ALEXANDER MAIR, SIR JAMES MACKENZIE, M.D., 1853-1925: GENERAL
PRACTITIONER (1986)).
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Dr. Curtis Hames, who practiced in Claxton, Georgia in the 1970s, wrote that his studies
were inspired by "the clinical observation that coronary heart disease appeared to occur
less frequently among blacks than whites, even though hypertension was obviously more
common in blacks and they consumed a higher animal fat diet."6 In his research, Dr.
Hames recorded extensive demographic details about his community including the
physical environment, socioeconomic conditions, family structures, and common
industries. 69

Reports from these innovators inspired primary care practitioners around the
world to begin to form regional and national research networks. One such example was
the Oxford Record Linkage Study where a total of 14,500 patients were "monitored for
contacts with their general practitioners via a computer-based weekly batching
system. 7 This undertaking successfully demonstrated that research data could be
collected alongside clinical care. 71 Moreover, in Australia, a pharmaceutical company
sponsored a six-year reporting study involving 50 general practitioners using
prescriptions written in triplicate as the primary means of data collection. 72 Family
doctors in Canada, who were participating in national surveillance to collect data to
characterize and track influenza cases, led to the formation of the Canadian National
Recording System and the creation of a PBRN which was operationalized through the
73
College of Family Physicians of Canada.
In the U.S., the rebranding of general practice as a new specialty, family
medicine, created new training programs in the late 1960s, which then created a demand
for systematic descriptions and classification systems that could inform the emerging
academic field. 74 These new opportunities for education and training of doctors in family
medicine specialties led to the development of the first regional PBRNs. 75 For example,
in 1974, Dr. James Perrin and his colleagues published a double-blind cross-over study
of methods for preventing inflammatory diseases of the middle ear.76 Medical schools,
philanthropic organizations, and federal grants and programs all provided funding for
77
this sort of work in the New EnglandJournalof/ledicine.
From these early regional networks, the Ambulatory Sentinel Practice of North
America was established in the early 1980s and initially for only three years. 7 For
example, one pivotal study focused on the treatment of headaches. 79 This network
collected data across practices in the U.S. and Canada and demonstrated that volunteer
physician participants could investigate practice generated research questions over time
that had the potential to improve care."0

68 Id.

at 2 (quoting Curtis G. Hames, Evans County Cardiovascular and Cerebrovascular

Epidemiologic Study, 128 ARCHIVES INTERNAL. MED. 883, 833 (1971)).
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These PBRNs, established during the 1970s through the 1990s, developed
without funding from traditional research sponsors, like the NIH and pharmaceutical
companies.81 Nationally, PBRNs were initially supported through the Health Resources
and Services Administration's ("HRSA") Title VII programs and for those8 2PBRNs
focused on pediatrics, through HRSA's Bureau of Maternal and Child Health.
However, in 2000, the AHRQ provided $2 million in grant funding to 19
emerging PBRNs to support the planning efforts and capacity building of these networks
to collect and analyze primary care data, to study healthcare delivery to minority and
underserved populations, and to translate these findings into practice.8 3 Based on the
success of these planning grants,
two-year capacity-building grants were awarded to an
84
additional seven networks.
From 2003 to 2006, AHRQ awarded small research grants and "translatingresearch-into -practice" grants to support the research endeavors of the newly established
networks.8 5 During this period, study projects included investigations of the feasibility
of implementing bidirectional disease registries, tobacco cessation intervention
effectiveness,6 and nurse-based telephonic interventions in acute asthma exacerbations
in children.
In 2012, AHRQ awarded eight grants to support the establishment of
collaborative research centers.8 7 Smaller, well-established research networks were
encouraged to work together to leverage common resources with the expectation that
these research centers would "improve productivity and to develop the ability to plan
and conduct independent research projects more quickly and produce results that are
more generalizable than they would as separate PBRNs .
8.8..""
These five-year awards
enabled networks to hire support and administrative staff to support research activities
and ensure a period of research core stability, which then allowed the aggregate
networks to apply for small grant funding to grow the capacity of the network to conduct
effective research.8 9
Although important to lay the groundwork for PBRNs, Steven Woolf has noted
that the federal research investment is dwarfed by its tens of billions of dollars of
investments in traditional research through the NIH, not to mention the hundreds of
billions more spent by industry. 9 In recent years, however, the NIH has begun to think
about how to connect these disparate parts of the healthcare knowledge generation
system. 91
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V.

THE ROLE OF PBRNS IN THE NIH ROADMAP

In the early aughts, the NIH introduced a "Roadmap Initiative" to focus on the
"translation" of basic research into human studies, and then into accepted treatments in
clinical practice.92 Elias Zerhouni, the then newly-appointed NIH Director, argued that
"continued success requires that the United States recast its entire system of clinical
research." 93 The Clinical and Translational Science Awards ("CTSA") have drawn the
greatest attention as the key parts of this roadmap. The CTSA program brought to life a
vision to improve the implementation of biomedical research, to shorten the time to
bring laboratory-based discoveries to routine care, to engage communities of providers
and patients in clinical research, and to train a new wave of clinical and translational
scientists.94 The CTSA Consortium, which started in 2006 with 12 awards,
has grown
95
to more than 50 institutions, with over $516 million in annual funding.
The notion of a roadmap frames this transportation analogy for thinking about
the geography of research, and specifically the need to link these academic centers as
the interstates/freeways, with practice-based research as the local highways. Ultimately,
a map emerges where research reaches the communities where most individuals live and
receive care.1
Continuing on the "road" metaphor, the NIIH's Clinical Research Roundtable
described multiple "roadblocks" in the clinical research enterprise, including "TI"
challenges to understand physiological mechanisms of disease and discovering potential
cures. 97 Just as important are the challenges of "T2"-"the translation of results from
'
clinical studies into everyday clinical practice and health decision making."98
Steven
Woolf writes that, "the 'laboratory' for T2 research is the community and ambulatory
care settings," where population based interventions and practice-based research
networks bring the results of T I research to the public. 99 "T2 requires different research
skills: mastery of the 'implementation science' of fielding and evaluating interventions
in real world settings ....100
The NIH identified PBRNs as a potential solution to the identified gap in
connecting research to practice, as research vehicles that conduct studies where most
patients receive their care and where that research is informed by practice
improvement. 101 Wesifall suggests that this notion has primarily just seen PBRNs as a
way to recruit patients into traditional clinical trials, but they can also:
(1) identify the problems that arise in daily practice that create the gap
between recommended care and actual care;
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(2) demonstrate whether treatments with proven efficacy are truly
effective and sustainable when provided in the real world setting of
ambulatory care; and
(3) provide the laboratory for testing system improvements in primary
care to maximize
the number of patients who benefit from medical
10 2
discovery.
PBRNs were seen to fit in well with the vision of the NIH Roadmap to "develop new
partnerships of research with organized patient communities, community based health
care providers... who care for sufficiently large groups of patients interested in working
with researchers to quickly develop test and deliver new interventions."' 1 3 CTSA
applicants and sites were encouraged to partner with at least one PBRN, as PBRNs must
invest considerable time and resources into cultivating long-term, collaborative
partnerships with their practicing clinicians, the practice sites, and patient
communities.104
Notwithstanding these ambitions, the relationship between CTSAs and PBRNs
has not been easy. In a 2008 survey of CTSA Community Engagement Directors and
PBRN Directors, the latter group identified the lack of sustainable and regular funding
as a barrier to partnerships. 0 5 Instead, the PBRN directors explained that funding was
provided on a project-by-project basis, which does not facilitate the development of
longer-term infrastructure and administrative services like personnel and
coordination.10 6 And, while CTSAs were encouraged to partner with PBRNs, even
applicant institutions were unaware of existing PBRNs within their own facilities and
staffed by their institution's clinical faculty. 107
The concerns went beyond finances and awareness. PBRNs identified a need
for sustained and continuous relationships to maintain trust and cooperation between
and amongst participating providers and clinical sites.10 8 Moreover, PBRNs also
emphasized the importance of having research topics emerge from the practicing
providers, or at least vetted by them; although CTSA recipients reported often seeking
out PBRNs as recruitment sites for university or academic investigations, they seemed
unaware of the need to cultivate ongoing, engaged, mutually beneficial relationships and
the importance of collaborating with clinical sites and providers to develop and
implement study protocols. 109
In early 2014, Professor Maureen Riley-Behringer of Elizabeth Town College
and her colleagues again surveyed the CTSA and PBRN directors.110 Compared to the
2008 survey, "PBRN Directors ... noted significantly greater use of CTSA resources
(i.e., informatics, training) and mostly highlighted growth and improvement in the
'
perceived relationships."111
Twice as many PBRN directors (51% vs. 240o) thought that
their organizations were important to the CTSAs, and triple as many thought that CTSAs
were "'very effective' in engaging with the PBRN." 112 Qualitatively, however, problems
112
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remain, as respondents indicated that, "the priorities of CTSAs and PBRNs do not
perfectly align, [and]
that CTSAs need to see PBRNs as more than a recruitment source
113
for clinical trials."
VI.

SUCCESSES AND STRENGTHS OF PBRNs

Putting aside the relationships between CTSAs and PBRNs, it is worthwhile to
consider PBRNs' own successes and challenges for advancing our knowledge about
drugs and devices more generally. They have a track record of both producing important
knowledge about drugs, and also bring a remarkably diverse population to research.114
PBRNs have already conducted successful real-world evidence based studies that have
addressed the treatment of common diseases and symptoms, prevention and early
diagnosis, organization and clinical systems, and continuity and coordination of care
using a variety of different research methodologies.115
While initial practice-based researchers have utilized case observations,
modem research networks and multi-site network collaborations have progressed to
using cross-sectional methods to prospective cohort studies (e.g., case-control studies
and randomized control studies).116 Some PBRNs have even conducted pragmatic
clinical trials, such as a 2013 dental study comparing two methods of capping teeth
across 35 practices and 376 individuals in the Northwest. 117 Still other PBRNs have
conducted individualized randomized trials of the effectiveness of drugs, such as a 2014
study of two different courses of prednisone treatments for severe poison ivy 118 and a
2012 study of azithromycin for adult asthma.119
PBRNs have provided real-world evidence for regulatory decision-making
regarding drug safety, specifically, using two web-based data collection interventions.
For example, a three-year project at the University of Oklahoma Health Sciences Center
developed and tested a patient-centered, prevention-oriented, web-based Wellness
Portal. 12' Following development, researchers studied the behavior and experiences of
121
patients using the Wellness Portal and the impact on patient-centered preventive care.
A cluster-RCT trial found that patients using the portal were more adherent to
recommended therapies, including aspirin use and pneumonia vaccination. 122
EMR has been a powerful tool for PBRNs, and has been particularly useful to
explore medication errors and adverse events. 123 In addition, four studies documented
3 Id. at 305.
at 302.
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improved medication use for patients, increased awareness for the need for medication
counseling, decreased medication errors, and identification
of best practices for
124
medication reconciliation in outpatient practice settings.
These demonstration projects were expanded to a national network in which
two error reporting studies were implemented across a total of 52 family practice sites,
in both rural and urban settings. 125 Reported errors were coded and reviewed for the
type, severity, and preventability of the error; the vast majority occurred during
prescribing, and were related to medication dose, medication selection, or the
medication itself.126
PBRNs were also important for the creation and testing of an ambulatory care
electronic Medication Errors and Adverse Drug Events Reporting System, which was
operationalized after pilot and feasibility testing of the system in four PBRNs, including
220 physicians and office staff from 24 practices. 127 The system was designed to reduce
errors and adverse events in primary care practices and to provide useful feedback to
those reporting events. 128 During a 10-week data collection period, 507 medication
events were reported, including problems ordering medication, implementing
prescription orders, errors by patients receiving the medication, and documentation
errors. 129 Only eight of these reports, however, were reported to the FDA's MedWatch
reporting system, which demonstrates the potential advantages of PBRN research over
such a passive system for collecting regulatory data. 131 Ultimately, the web-based
medication event reporting system was proven to successfully collect
medication data
131
with minimal practice interruption and clinician time expenditure.
As of 2007, three quarters of PBRN networks were affiliated with a university
or academic center.132 PBRNs provide academic researchers vital access to underresearched and underrepresented populations. Compared to national data regarding
persons seeking healthcare and national population estimates, PBRN practices have
higher percentages of patients who were of African American race, Hispanic ethnicity,
133
and who were more likely to not have private insurance.
Trust is an important predictor of willingness to participate in research, and this
is especially true for minority populations. 134 PBRNs engender trust through a long-term
engagement with the communities they serve and a population of diverse researchers
(2017) (finding that almost two-thirds of surveyed PBRNs had electronic data capture through an EMR);
Grace M. Kuo et al., ConductingMedication Safety Research Projects in a PrimaryCarePhysician PracticeBased Research Network, 48 J. AM. PHARMACISTS ASS'N 163 (2008) (describing four research projects
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actively treating diverse patients. For example, the PRImary care MultiEthnic Network
("PRIME Net") is a consortium of networks that share a commitment to improving the
clinical care of underserved and underrepresented populations.135 Across five
underserved populations-African American, Chaldeans/Arab, Chinese, Hispanic, and
Navajo-individual members emphasized "that establishing and maintaining trust
through a set of relationship building activities, through communications, and through
ensuring appropriate return to the community [was] essential." 136 As Professor Christina
Getrich and her colleagues explain, PBRNs can cultivate "respectful relationships,
bidirectional communication, and useful return of results," and thereby "maximize their
ability to link clinicians, underrepresented communities, and researchers in meaningful
research." 13 7

While it is important to have access to minority, underserved, and
underrepresented populations, PBRNs can also shape the research itself. Surveys
demonstrate that research ideas come from collaboration between researchers and
clinicians as well as outside investigators,138 and that study protocols were enhanced and
improved by including clinicians and staff in the design process, and development. 139
VII.

CHALLENGES FOR PBRNs

Notwithstanding these documented successes, PBRNs face challenges. First,
they have unique research cultures. They are not simply hierarchical agencies whose
physicians can be directed to perform this or that project; instead the physician networks
must select fundable and feasible studies that are of interest and importance to
members.140 Second, PBRNs must create detailed, practical budgets that reflect the
reality of the study, without underestimating the cost and time needed to implement a
network study. 141 Building the research capacity of primary care providers and their staff
is also essential. Different training modalities-face-to-face, online, or some
combination thereof-are typically used to train providers and their staff who are
participating in a study to ensure consistency of the protocol implementation. 142
Clinicians are first and foremost healthcare providers. Their performance
evaluations and professional responsibilities lie in completing patient visits and the tasks
associated with patient care. Dr. Justin Altschuler of the University of California, and
his colleagues, estimate that the average family practice provider has a panel of
approximately 2,300 patients, and it would take 21.7 hours per day to provide the
recommended acute, chronic, and preventative care for all these patients. 143
Accordingly, most primary care providers do not have the time in their schedules to
address all the clinical needs of their patients, let alone conduct rigorous real-world
evidence generating research. Office staff and work flow processes within primary care
offices can also limit the feasibility of implementing practice-based research.
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On the other hand, clinicians reportedly join PBRNs for camaraderie and from
a desire to improve care and outcomes for their patients. 144 Since the 1980s, the rate at
which physicians say that research is a major part of theirjob has fallen precipitously. 145
Yet when one is merely in the business of applying, but not generating, knowledge,
medicine can begin to seem like a rote exercise in repetition -- applying the same
standard care over and over. In contrast, Dr. James Mold of the University of Oklahoma
and Dr. Kevin Peterson of the University of Minnesota describe PBRNs as "learning
communities," which enrich the practices of their members.146 Indeed PBRN
participation has been shown to positively impact the retention of providers in rural and
underserved communities. In a study of 22 rural and underserved clinics in New Mexico,
with 95 physicians, nurse practitioners, and physician assistants, the average length of
employment was three years longer for research network members compared to nonmembers.147 When asked why they participated in such research networks, physicians
said that they appreciated the "opportunity to enact 148
quality improvement, contribution
to clinical knowledge, and intellectual stimulation."
Financial support and long-term sustainability has been a substantial and longterm challenge for PBRNs. Most networks struggle to support themselves through grant
funding, which limits long-term planning and recruitment and retention of key support
personnel for research networks. 149 Although funding from AHRQ and the NIH through
CTSAs consistently reaches some PBRNs, other PBRNs do not receive funding and still
struggle with establishing an administrative and coordination core. 150
To the extent that PBRNs begin generating substantial data for FDA regulatory
filings, much of that funding may come from the drug and device industries, who stand
to benefit from securing and maintaining broader FDA approvals. 151 Industry funding
152
raises its own problems for the integrity of, and public trust in, biomedical science.
153
AMCs have found it challenging to negotiate these relationships with industry,
and
PBRNs will be similarly challenged. Of critical importance is securing the freedom to
publish results regardless of success or failure, subject to a review and comment clause
within the research contract. 154 Even AMCs have been found to publish the results of
only about two-thirds of the trials they perform. 155 Nonetheless, the breadth of PBRNs,
stretching across dozens of practices and hundreds of physicians, may diffuse the power
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of the funder to extract preferred results from individual investigators.156 The PBRN
system may itself serve to insulate individual physicians from the corrupting power of
money.
The FDA may also help insulate PBRNs from direct industry funding by
collecting and then directing some of the FDA user fees collected from the drug and
device industry towards a national coordinating center, which could also receive and
distribute project-specific funding from particular companies to investigate their
products in real -world settings. The FDA recently announced its fiscal year 2019 budget,
which includes an additional $400 million in funding, including funding prioritizing the
"advance[ment of] the use of real-world evidence to better inform patient care and
provide more efficient, robust and potentially lower cost ways to develop clinical data
'
that inform product review and promote innovation."157
This funding could be used to
pilot the use of PBRNs in generating post-marketing safety and effectiveness data
regarding the real-world use of drugs.
VIII.

RECOMMENDATIONS AND CONCLUSIONS

PBRNs show promise as an avenue for the collection of "real-world evidence"
for new indicated uses of approved drugs and to supplement or substantiate required
post-approval studies, as the 2 1 s Century Cures Act contemplates. PBRNs can produce
real-world evidence for regulatory science more generally. The community-based
settings of PBRNs can generate, identify, and analyze large amounts of data from
diverse patient populations across racial, ethnic, socioeconomic, and geographic areas,
which are collected in the context of the patient's medical home.
Preliminary research shows that patients, especially those from populations
generally underrepresented in clinical trials, may feel more comfortable participating in
research directly connected with trusted primary care providers.158 The larger and morediverse number of patients recruited in existing PBRN studies suggests that point-ofcare data may be a robust method to identifying multi-drug interactions and side effects
of approved drugs in the future.
Although many have interpreted the "real-world evidence" mandate as being
hostile to randomization, such a characterization is shortsighted. Instead, PBRNs have
proven that it is possible to roll out larger randomized trials embracing broad
populations, clustered at the level of individual physicians or practices. Accordingly, the
gold standard for causal inference can be retained even outside the rarefied settings of
traditional clinical trials.
PBRNs are a mechanism to make U.S. healthcare slightly less fragmented by
tying together practitioners and then engaging them in the research enterprise,
contributing to regulatory science. While PBRNs have grown from the grassroots of
primary care, Congress should create a regular and substantial source of funding for
PBRNs to reach their fullest potential. If the mandate advocates bringing real-world
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evidence into regulatory science, we will need to invest in our infrastructure for
generating that science.
Even beyond this mandate set by the 21st Century Cures Act, PBRNs hold great
promise to inform the healthcare practice. Increasingly, the binary question of whether
the FDA will or will not permit a new drug indication to appear on the label is becoming
less important-patients demand prescriptions for off-label uses and unapproved
drugs.159 Nonetheless, providers, payors, and patients still demand stronger proof of
clinical effectiveness and value for the scarce healthcare dollar. 160 Not every approved
drug will be reimbursed for every use. Thus, the Centers for Medicare and Medicaid
Services, along with the private insurance industry, also have a stake in real-world
evidence and information about effectiveness beyond efficacy.
Accordingly, the 2 1st Century Cures Act's demand for "real-world evidence"
is likely only the beginning of a much broader agenda. PBRNs may have a key role to
play in obtaining large amounts of data in rigorous research designs from diverse
populations in primary care medical settings.
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